GSS EU Science Funding Gateway

Proposals should address all of the following:

• Design and conduct randomised or cluster-randomised academic investigator-initiated pragmatic clinical trials to deliver effective and evidence-based diagnostic interventions for implementation by healthcare systems at the level of local communities, European regions, Member States and Associated Countries, taking into account stratification, such as biology, molecular features, sex, gender, cancer stage, and age. Clinical trial design and conduct could be aided by computational, simulation and visualisation tools and technologies where appropriate.
• The chosen diagnostic intervention(s) should be adapted to the particular needs of the target population and to the specificities of the provision of care at local, regional, or national level, duly reflecting the diversity across Member States and Associated Countries. Furthermore, affordability and accessibility should be taken into account.
• The successful proposals should clearly justify and describe the evidence supporting the chosen diagnostic intervention.
• The primary and secondary endpoints of the pragmatic clinical trial should support overall survival, patient-reported outcomes and quality of life issues considered important by and for cancer patients and their caregivers.
• Such endpoints should be defined together with patients and their caregivers through research that uses open knowledge, (social) innovation systems and support end-user engagement, such as living labs or other participative research models.
• Successful pragmatic clinical trials, including their analyses, should be completed within 5 years from the start of the project. Translational research is not within the scope of this topic.
• In all instances, sex- and gender-related issues must be taken into account. All data should be disaggregated by sex, gender, age and other relevant variables, such as by measures of socio-economic status or ethnicity.